Alan Fuhrman (L) and Barry Labinger (Checkmate)

Check­mate CEO hits the ex­it as Art Krieg's crew strug­gles to warm in­vestors to TLR9 strat­e­gy

Al­most three years af­ter pick­ing up the ba­ton from Art Krieg to help steer Check­mate’s TLR9 ag­o­nist deep­er in­to the clin­ic, CEO Bar­ry Labinger is out.

Alan Fuhrman, a board mem­ber and chair­man of the au­dit com­mit­tee, has stepped in to fill the in­ter­im pres­i­dent and CEO role, steady­ing the ship with his back­ground in fi­nan­cial op­er­a­tions. A for­mer board di­rec­tor at Loxo On­col­o­gy, Fuhrman has al­so been CFO at Am­plyx, Mir­na and Am­bit.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA